



***Small but heading for the big time***

***Nanobiotix expands operations into the USA as part of its international development strategy***

***Affiliate opened in the Massachusetts Life Sciences Center***

***A senior pharmaceutical executive appointed as Vice President Corporate Development***

**Paris, France, September 22, 2014 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

Laurent Lévy, CEO of Nanobiotix, and Deval Patrick, Governor of Massachusetts state, officially announced the opening of the company's US affiliate during a ceremony on Friday September 19, 2014 at the US embassy in Paris, France, in the presence of Dr Susan Windham-Bannister, CEO and President of the Massachusetts Life Sciences Center.

The opening of the affiliate in Boston area is an important step for Nanobiotix's international development strategy. The Massachusetts life science cluster is recognized worldwide for its critical number of high-quality academic centers and biopharma companies. Developing company's operations in the Boston life sciences and nanomedicine hub will provide Nanobiotix with the access to the knowhow and high level expertise of the research.

This move is the next step of Nanobiotix's International expansion, allowing the company to work closer to the US industrial and financial communities.

This environment should benefit to the company's potential future development beyond NanoXray.

Laurent Lévy, Chief Executive Officer at Nanobiotix, commented: *"The opening of a US affiliate is a key strategic step for Nanobiotix's international ambitions. The Boston area is the ideal location for us to access new talent, innovative research and clinical expertise in the nanomedicine."*

To lead the development of the US affiliate, Patrick Tricoli has been appointed Vice President Corporate Development for Nanobiotix. Patrick has over 25 years' experience within the pharmaceutical industry and joins Nanobiotix from Sanofi where he held a number of positions in both Corporate and Research and Development. In recent years Patrick has focused on international business development and partnering activities. He is a doctor of Pharmaceutical Sciences, he holds a master degree in Pharmacology and Pharmacokinetics, and he is an Executive MBA from ESCP Europe.

Patrick Tricoli commented: *"Among hundreds of innovative projects I reviewed in my previous roles with both R&D and Business Development perspectives, I am firmly convinced that Nanobiotix' disruptive approach could be the future of the healthcare industry. I am pleased to join this team with whom I share the same values, ambitions and passion."*

**-Ends-**

## About NANObIOTIX: [www.nanobiotix.com](http://www.nanobiotix.com)

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers (Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, H&N cancer, Glioblastoma, Prostate...) via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP).

## Contacts

<i>Nanobiotix</i>	<i>Financial communication and investors relations</i>	
<b>Sarah Gaubert</b> <i>Head of Communication and Public Affairs</i> +33 (0)1 40 26 07 55 <a href="mailto:contact@nanobiotix.com">contact@nanobiotix.com</a>	<b>NewCap</b> <b>Emmanuel Huynh</b> +33 (0)1 44 71 98 53 <a href="mailto:lvdelouvrier@newcap.fr">lvdelouvrier@newcap.fr</a>	
<i>Media relations</i>		
France - <b>NewCap</b> <b>Annie-Florence Loyer</b> +33 (0) 1 44 71 94 93 <a href="mailto:afloyer@newcap.fr">afloyer@newcap.fr</a>	Outside France - <b>Instinctif Partners</b> <b>Melanie Toyne Sewell / Katherine Lynch</b> +44 (0) 207 457 2020 <a href="mailto:nanobiotix@instinctif.com">nanobiotix@instinctif.com</a>	

## Disclaimer

*This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the 2013 financial annual report of Nanobiotix (a copy of which is available on [www.nanobiotix.com](http://www.nanobiotix.com)) and to developments in general economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.*